[Abstract Only] Randomized Trial: Metformin May Reduce Metabolic Complications and Inflammation in Patients on Systemic Glucocorticoid Therapy

Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)

Commentaries: Metformin could mitigate glucocorticoid-related complications – Medicine Matters (free) AND Metabolic effects of glucocorticoids reversed with metformin – Healio (free registration required) AND Diabetes Drug May Benefit Long-Term Steroid Users – MedPage Today (free registration required)